Knowledge, Attitude, and Practice Towards Biosimilars and Interchangeable Products: A Prescriptive Insight by the Pharmacists.
Pakistan
biosimilar medicines
healthcare
interchangeable products
pharmacists
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
06
2020
accepted:
07
08
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
19
11
2020
Statut:
epublish
Résumé
Pharmacists being the drug experts need to be well aware of the applied handling of biosimilar medicines (BSMs). They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings. Therefore, the current study was conducted to assess the pharmacists' knowledge, attitude, and practices of integrating BSMs into clinical practice. The cross-sectional study was conducted from August 2019 to November 2019. The community pharmacies, clinical and academic settings in Karachi were approached for gathering the responses of pharmacists towards BSMs and interchangeable products using a 30-item survey form. Pearson correlation and independent sample Overall, there were 305 survey forms used with a response rate of 87.14%. More than 80% of the respondents have good knowledge about the definition, characteristics, safety and efficacy, compatibility, cost issues, and utilization of BSMs. Around half of the respondents (48.9%, [95% CI 46.6-51.2]) were confident in using BSMs in clinical practice. However, they were concerned about the BSM's safety profile (45.2%, [95% CI 42.1-48.3]), quality (30.2%, [95% CI 28.3-32.1]), and efficacy issues (32.3%, [95% CI 31.2-37.5]). The findings revealed that pharmacists were well informed about the BSMs. However, some of the responses to the attitude demonstrated a lack of understanding of the application of that knowledge. The respondents persuaded that advanced patterns of diseases, product marketing stipulations, and need for better patient care drives higher demand for developing BSMs and were enthusiastic about gaining more insight to integrate BSMs into routine clinical practice.
Sections du résumé
BACKGROUND
BACKGROUND
Pharmacists being the drug experts need to be well aware of the applied handling of biosimilar medicines (BSMs). They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings. Therefore, the current study was conducted to assess the pharmacists' knowledge, attitude, and practices of integrating BSMs into clinical practice.
METHODS
METHODS
The cross-sectional study was conducted from August 2019 to November 2019. The community pharmacies, clinical and academic settings in Karachi were approached for gathering the responses of pharmacists towards BSMs and interchangeable products using a 30-item survey form. Pearson correlation and independent sample
RESULTS
RESULTS
Overall, there were 305 survey forms used with a response rate of 87.14%. More than 80% of the respondents have good knowledge about the definition, characteristics, safety and efficacy, compatibility, cost issues, and utilization of BSMs. Around half of the respondents (48.9%, [95% CI 46.6-51.2]) were confident in using BSMs in clinical practice. However, they were concerned about the BSM's safety profile (45.2%, [95% CI 42.1-48.3]), quality (30.2%, [95% CI 28.3-32.1]), and efficacy issues (32.3%, [95% CI 31.2-37.5]).
CONCLUSION
CONCLUSIONS
The findings revealed that pharmacists were well informed about the BSMs. However, some of the responses to the attitude demonstrated a lack of understanding of the application of that knowledge. The respondents persuaded that advanced patterns of diseases, product marketing stipulations, and need for better patient care drives higher demand for developing BSMs and were enthusiastic about gaining more insight to integrate BSMs into routine clinical practice.
Identifiants
pubmed: 33204142
doi: 10.2147/IJGM.S266545
pii: 266545
pmc: PMC7667000
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1075-1082Informations de copyright
© 2020 Shakeel et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
J Ren Care. 2015 Mar;41(1):53-61
pubmed: 25348203
Eur J Hosp Pharm. 2019 Mar;26(2):117-118
pubmed: 31157111
J Oncol Pharm Pract. 2020 Apr;26(3_suppl):22-32
pubmed: 32268828
Semin Arthritis Rheum. 2016 Apr;45(5 Suppl):S11-8
pubmed: 26947440
Nat Biotechnol. 2011 Apr;29(4):310-2
pubmed: 21478841
Pharmaceuticals (Basel). 2012 Mar 30;5(4):353-68
pubmed: 24281406
Adv Ther. 2017 Jan;33(12):2160-2172
pubmed: 27798772
Reumatologia. 2018;56(4):234-242
pubmed: 30237628
PeerJ. 2018 Aug 30;6:e5481
pubmed: 30186686
BMJ Open. 2017 Jun 21;7(6):e016730
pubmed: 28637743
BMJ Open. 2018 Nov 18;8(11):e023603
pubmed: 30455389
Hosp Pharm. 2015 Nov;50(10):884-893
pubmed: 27729676
Arthritis Rheum. 2011 Oct;63(10):2848-50
pubmed: 21702015
BioDrugs. 2018 Oct;32(5):499-506
pubmed: 30120705
Ann Pharmacother. 2017 Jul;51(7):590-602
pubmed: 28176529
Nat Rev Drug Discov. 2014 Feb;13(2):99-100
pubmed: 24445562
Clinicoecon Outcomes Res. 2011;3:29-36
pubmed: 21935330
MAbs. 2017 Feb/Mar;9(2):383-390
pubmed: 27929743
Regul Toxicol Pharmacol. 2017 Aug;88:252-261
pubmed: 28666961
Autoimmun Rev. 2014 Jun;13(6):678-84
pubmed: 24440285
Blood. 2014 Nov 20;124(22):3191-6
pubmed: 25298038
J Dermatolog Treat. 2015;26(4):299-302
pubmed: 26105205
Health Aff (Millwood). 2015 Feb;34(2):294-301
pubmed: 25646110
Expert Opin Biol Ther. 2013 Jul;13(7):1039-47
pubmed: 23527621
AAPS J. 2014 Jan;16(1):11-4
pubmed: 24065599
Health Aff (Millwood). 2011 Nov;30(11):2157-66
pubmed: 22068409
Ther Adv Med Oncol. 2019 Jan 06;11:1758835918818335
pubmed: 30671144
Stat Med. 2013 Feb 10;32(3):370-81
pubmed: 22933240